clinical trial · NCT02988297
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral SclerosisRNS60Placebo
brief summary
The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
started
Oct 1, 2026
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Apr 16, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol